27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Biogen Inc (NASDAQ:BIIB) shares were trading higher Wednesday following the issuing of a decision by the U.S. Patent and Trademark Office's Patent Trial and Appeal Board on a patent trial challenge by Mylan NV (NASDAQ:MYL) on '514 Tecfidera that was in Biogen's favor.
See Also: 9 Takeaways From The JPMorgan Healthcare Conference
Biogen’s top product is a multiple sclerosis drug, Tecfidera. Mylan had asked the U.S. Patent and Trademark Office to take a look at Biogen’s exclusive hold on Tecfidera until 2028, according to Barron’s.
Biogen shares were trading 24.62% higher at $353.04 at the time of publication, while Mylan shares were up 2.49% at $22.82.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!